AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|AAPL316.85-2.85 (-0.89%) ▼|ABBV256.42+0.94 (+0.37%) ▲|ABT110.36-2.11 (-1.88%) ▼|ACN189.76+0.15 (+0.08%) ▲|ADBE292.79+1.27 (+0.44%) ▲|AMAT458.39-3.28 (-0.71%) ▼|AMD470.72+5.14 (+1.10%) ▲|AMGN429.88-2.54 (-0.59%) ▼|AMT175.70-0.53 (-0.30%) ▼|AMZN259.77-6.66 (-2.50%) ▼|AVGO370.34+1.55 (+0.42%) ▲|AXP330.17-3.03 (-0.91%) ▼|BA207.78-2.04 (-0.97%) ▼|BAC61.94-0.38 (-0.61%) ▼|BKNG199.09-6.54 (-3.18%) ▼|BLK1,155.61-8.87 (-0.76%) ▼|BMY66.81+0.23 (+0.35%) ▲|BNY161.28-1.22 (-0.75%) ▼|BRK-B504.03-0.97 (-0.19%) ▼|C131.62-1.28 (-0.96%) ▼|CAT797.47-2.78 (-0.35%) ▼|CL89.82-0.93 (-1.02%) ▼|CMCSA26.62-0.44 (-1.63%) ▼|COF214.51-1.16 (-0.54%) ▼|COP132.49+2.14 (+1.64%) ▲|COST943.89-1.58 (-0.17%) ▼|CRM257.54+1.54 (+0.60%) ▲|CSCO110.49+0.56 (+0.51%) ▲|CVS93.91+0.85 (+0.91%) ▲|CVX206.14+4.28 (+2.12%) ▲|DE654.91+24.58 (+3.90%) ▲|DHR213.56-2.51 (-1.16%) ▼|DIS107.55-0.55 (-0.51%) ▼|DUK119.91-0.34 (-0.28%) ▼|EMR152.44-2.74 (-1.77%) ▼|FDX327.40-3.48 (-1.05%) ▼|GD371.35-7.97 (-2.10%) ▼|GE335.71-6.87 (-2.01%) ▼|GEV898.53-13.40 (-1.47%) ▼|GILD146.34+0.66 (+0.45%) ▲|GM86.32+0.05 (+0.06%) ▲|GOOG335.41-7.47 (-2.18%) ▼|GOOGL339.35-7.24 (-2.09%) ▼|GS1,025.90-8.09 (-0.78%) ▼|HD327.83-2.36 (-0.71%) ▼|HON213.53-3.90 (-1.79%) ▼|IBM233.87-1.72 (-0.73%) ▼|INTC89.51+0.04 (+0.04%) ▲|INTU359.30+1.24 (+0.35%) ▲|ISRG376.86+4.26 (+1.14%) ▲|JNJ265.85-2.19 (-0.82%) ▼|JPM356.02-1.60 (-0.45%) ▼|KO88.67-0.99 (-1.10%) ▼|LIN489.58+0.07 (+0.01%) ▲|LLY1,156.73-17.88 (-1.52%) ▼|LMT561.23-2.62 (-0.46%) ▼|LOW204.70-3.35 (-1.61%) ▼|LRCX301.49-0.41 (-0.14%) ▼|MA589.31-5.99 (-1.01%) ▼|MCD263.54-1.46 (-0.55%) ▼|MDLZ62.07-0.29 (-0.47%) ▼|MDT90.65-0.58 (-0.64%) ▼|META572.34-5.68 (-0.98%) ▼|MMM171.83-2.51 (-1.44%) ▼|MO68.48-0.17 (-0.25%) ▼|MRK147.76-0.59 (-0.40%) ▼|MS213.32-1.45 (-0.68%) ▼|MSFT507.29-6.24 (-1.22%) ▼|MU958.73+25.87 (+2.77%) ▲|NEE82.34+0.50 (+0.61%) ▲|NFLX81.05-0.67 (-0.82%) ▼|NKE39.06-0.54 (-1.36%) ▼|NOW147.99+3.28 (+2.27%) ▲|NVDA220.78+3.23 (+1.48%) ▲|ORCL149.12-1.73 (-1.15%) ▼|PEP140.34-0.73 (-0.52%) ▼|PFE28.46+0.50 (+1.79%) ▲|PG145.12+1.34 (+0.93%) ▲|PLTR186.38+0.09 (+0.05%) ▲|PM187.30-4.59 (-2.39%) ▼|QCOM170.48+6.29 (+3.83%) ▲|RTX207.73-3.98 (-1.88%) ▼|SBUX106.25-1.60 (-1.48%) ▼|SCHW109.82-0.34 (-0.31%) ▼|SO88.00-0.25 (-0.28%) ▼|SPG212.32-2.24 (-1.04%) ▼|T25.89-0.12 (-0.46%) ▼|TMO617.10-5.08 (-0.82%) ▼|TMUS180.44-0.93 (-0.51%) ▼|TSLA367.95+19.20 (+5.51%) ▲|TXN260.91+2.27 (+0.88%) ▲|UBER75.65-3.17 (-4.02%) ▼|UNH389.41-3.54 (-0.90%) ▼|UNP300.67-5.32 (-1.74%) ▼|UPS104.23-1.10 (-1.04%) ▼|USB61.58-0.89 (-1.42%) ▼|V379.37-2.23 (-0.58%) ▼|VZ50.02-0.08 (-0.16%) ▼|WFC86.39-0.30 (-0.35%) ▼|WMT104.87+1.78 (+1.73%) ▲|XOM160.95+4.24 (+2.71%) ▲|
22.3 C
New York
Tuesday, September 1, 2026

Tag: test

newssourceFORcompanyinformationcontent1releasesmarket

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Lilly’s Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with...

BRUIN CLL-322 is the first Phase 3 study to demonstrate superiority over a venetoclax-containing control arm in CLL, and, with the majority of patients...

Marler Clark Urges Parents to Stop Using Nara Organics Whole Milk Organic Powdered Infant Formula Amid Multistate Infant Botulism Outbreak — Product Sold Nationwide...

FDA, CDC, and public health officials in California, Pennsylvania, and Washington are investigating; food safety attorney Bill Marler calls it the second formula-linked infant...

“New US Social Casino Bonus: 200% Match + 10 SC Coins” – by Acebet

Acebet social casino now credits 10 free Sweeps Coins at signup, no purchase required, and matches a player's first Gold Coin package at 200%: making this the best social casino signup bonus as of June 2026. 
Acebet social casino now credits 10 free Sweeps Coins at signup, no purchase required, and matches a player's first Gold Coin package at 200%: making this the best social casino signup bonus as of June 2026.

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

EpiCooler Product Information Updated As Consumer Interest In Portable AC Grows In 2026

Kaunas, Lithuania, June 13, 2026 (GLOBE NEWSWIRE) --

An informational overview examining EpiCooler Portable AC Product Details, Publicly available product disclosures and what consumers often consider when researching portable cooling devices in 2026

GRAL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that GRAIL, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges that Grail’s top executives made false and/or misleading statements to investors.

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec...

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins

Traws Pharma Provides Regulatory Update on Influenza Program

NEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced that the planned test of tivoxavir marboxil (TXM) in a Phase 2a human influenza challenge study has been deferred due to a negative review of the program by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA).

PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone...

Allegheny Health Network’s Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types

Systemwide research initiative uses blood‑based genomics to improve early detection and personalize cancer treatmentPITTSBURGH, June 12, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) Cancer...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTest

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers